TTBK1 Inhibitors
TTBK1 inhibitors as a chemical class is not extensively characterized due to the specificity of TTBK1's role and the nascent research on direct inhibitors. However, as TTBK1 is a kinase, it shares structural features with other kinases, which means that inhibitors designed for one kinase may have some degree of cross-reactivity with others. Kinase inhibitors often target the ATP-binding site of the enzyme, which is relatively conserved across the kinase family. Therefore, broad-spectrum kinase inhibitors such as Staurosporine and its analogs, like K252a, could inhibit TTBK1 by competing with ATP for binding to the kinase domain.
Other inhibitors listed above were originally designed to target other kinases or cellular targets but may affect TTBK1 due to the broad nature of their action or through indirect effects on cellular signaling pathways. For example, inhibitors like Harmine, which targets DYRK1A, a kinase structurally similar to TTBK1, could inhibit TTBK1 as well. Similarly, multitargeted kinase inhibitors like Sunitinib and Sorafenib, which are designed to inhibit multiple receptor tyrosine kinases involved in cancer cell proliferation and angiogenesis, might also inhibit TTBK1 as part of their broad-spectrum activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent, non-selective inhibitor of protein kinases that may inhibit TTBK1 among many others. | ||||||
K-252a | 99533-80-9 | sc-200517 sc-200517B sc-200517A | 100 µg 500 µg 1 mg | $129.00 $214.00 $498.00 | 19 | |
A staurosporine analog that inhibits a number of kinases and could potentially inhibit TTBK1. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $153.00 $464.00 | 20 | |
An adenosine kinase inhibitor that may indirectly affect TTBK1 by altering ATP levels. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
A cyclin-dependent kinase inhibitor that may have cross-reactivity with TTBK1. | ||||||
Harmine | 442-51-3 | sc-202644 sc-202644A sc-202644B sc-202644C sc-202644D sc-202644E sc-202644F | 250 mg 500 mg 1 g 10 g 50 g 100 g 500 g | $53.00 $104.00 $126.00 $551.00 $1467.00 $2611.00 $11455.00 | 2 | |
A DYRK1A inhibitor that could potentially inhibit TTBK1 due to structural similarities in the kinase domain. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
An inhibitor of cyclin-dependent kinases and GSK-3β that might affect TTBK1 indirectly. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
A checkpoint kinase inhibitor that could potentially inhibit TTBK1 through off-target effects. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK) that can have broad kinase inhibitory effects. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
A RAF kinase inhibitor that could potentially inhibit TTBK1 due to kinase cross-reactivity. | ||||||
Lestaurtinib | 111358-88-4 | sc-218657 sc-218657A sc-218657B | 1 mg 5 mg 10 mg | $275.00 $326.00 $612.00 | 3 | |
Originally developed as a JAK2 inhibitor, it has a broad spectrum of kinase inhibition which may include TTBK1. | ||||||